CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.9%

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) shares traded down 0.9% on Monday . The stock traded as low as $66.50 and last traded at $67.52. 397,058 shares were traded during trading, a decline of 80% from the average session volume of 1,941,086 shares. The stock had previously closed at $68.16.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Morgan Stanley raised their price objective on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an "underweight" rating in a research report on Monday, February 26th. TheStreet raised shares of CRISPR Therapeutics from a "d+" rating to a "c" rating in a research report on Friday, February 23rd. Chardan Capital raised their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a "buy" rating in a research report on Thursday, February 22nd. Barclays increased their price target on CRISPR Therapeutics from $61.00 to $80.00 and gave the company an "equal weight" rating in a report on Thursday, February 22nd. Finally, Needham & Company LLC increased their price target on CRISPR Therapeutics from $88.00 to $90.00 and gave the company a "buy" rating in a report on Wednesday, February 21st. Three analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $74.75.

CRISPR Therapeutics Price Performance

The firm's 50 day moving average price is $74.02 and its 200-day moving average price is $62.04. The firm has a market cap of $5.47 billion, a price-to-earnings ratio of -34.45 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to analyst estimates of $148.72 million. The company's revenue was up 3253.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.41) EPS. Analysts expect that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 50,000 shares of the firm's stock in a transaction on Monday, January 29th. The stock was sold at an average price of $60.51, for a total value of $3,025,500.00. Following the completion of the transaction, the chief executive officer now directly owns 187,377 shares of the company's stock, valued at $11,338,182.27. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Raju Prasad sold 3,524 shares of the firm's stock in a transaction on Friday, March 15th. The stock was sold at an average price of $72.69, for a total value of $256,159.56. Following the completion of the transaction, the chief financial officer now directly owns 6,476 shares of the company's stock, valued at $470,740.44. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock in a transaction on Monday, January 29th. The shares were sold at an average price of $60.51, for a total value of $3,025,500.00. Following the transaction, the chief executive officer now directly owns 187,377 shares of the company's stock, valued at $11,338,182.27. The disclosure for this sale can be found here. Insiders sold a total of 134,410 shares of company stock valued at $9,234,677 over the last ninety days. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CRSP. CWM LLC lifted its holdings in shares of CRISPR Therapeutics by 80.7% during the third quarter. CWM LLC now owns 582 shares of the company's stock valued at $26,000 after acquiring an additional 260 shares during the period. Tradewinds Capital Management LLC lifted its holdings in shares of CRISPR Therapeutics by 545.5% during the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company's stock valued at $32,000 after acquiring an additional 600 shares during the period. Blue Trust Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $32,000. Headlands Technologies LLC bought a new position in shares of CRISPR Therapeutics in the third quarter valued at about $34,000. Finally, Bourgeon Capital Management LLC raised its holdings in shares of CRISPR Therapeutics by 1,000.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company's stock valued at $34,000 after buying an additional 500 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.